Journey Medical Corp reports results for the quarter ended June 30 - Earnings Summary

Journey Medical

12/08/2026 22:01

Journey Medical Corp DERM.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -16 cents.  The mean expectation of four analysts for the quarter was for a loss of 2 cents per share. Wall Street expected results to range from -7 cents to 6 cents per share.
Revenue rose 23.3% to $18.51 million from a year ago; analysts expected $18.37 million. 
Journey Medical Corp's reported EPS for the quarter was a loss of 1 cent​.
The company reported a quarterly loss of $312 thousand.
Journey Medical Corp shares had fallen by 10.7% this quarter and lost 18.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 12.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Journey Medical Corp is $13.00, about 51.4% above its last closing price of $6.32
This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.02
-0.01
Beat
Mar. 31 2026 
-0.08
-0.08
Met
Dec. 31 2025 
-0.06
-0.05
Beat
Sep. 30 2025 
-0.05
-0.09
Missed